Resultados de la búsqueda 21-30 of 4836 for Dafalgan side effects

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this combination ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental ...

  4. Hematología - Ensayos clínicos - Mayo Clinic

    This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Due to the intensive nature of CAR-T treatment and its unique side effects ... side effects, and improve immune function. Information learned from this ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental ...

  9. Mayo Clinic Physician Update - February 2025

    Page 1.

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...